Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis
202451 citationsMark H. Ebell, Henry C Barry et al.The Annals of Family Medicineprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Henry C Barry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry C Barry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry C Barry more than expected).
This network shows the impact of papers produced by Henry C Barry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry C Barry. The network helps show where Henry C Barry may publish in the future.
Co-authorship network of co-authors of Henry C Barry
This figure shows the co-authorship network connecting the top 25 collaborators of Henry C Barry.
A scholar is included among the top collaborators of Henry C Barry based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Henry C Barry. Henry C Barry is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Ebell, Mark H., et al.. (2024). Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis. The Annals of Family Medicine. 22(1). 50–62.51 indexed citations breakdown →
3.
Barry, Henry C. (2024). Scottish Screening: No Cases of Invasive Cervical Cancer in Women Who Received at Least One Dose of Bivalent HPV Vaccine at 12 or 13 Years of Age.. PubMed. 110(2). 201–202.1 indexed citations
4.
Ebell, Mark H. & Henry C Barry. (2022). Why Physicians Should Not Prescribe Aducanumab for Alzheimer Disease.. PubMed. 105(4). 353–354.10 indexed citations
5.
Barry, Henry C. (2021). Ultrasonography Is Accurate for Diagnosing Upper Extremity Fractures in Children.. PubMed. 104(6). Online–Online.1 indexed citations
Barry, Henry C. (2019). Platelet-Rich Plasma is Equal to Saline for Patients with Patellar Tendinopathy.. PubMed. 100(12). Online–Online.1 indexed citations
Barry, Henry C, et al.. (2002). Family physicians' use of medical abstracts to guide decision making: style or substance?. PubMed. 14(6). 437–42.94 indexed citations
15.
Barry, Henry C, et al.. (2001). A randomized controlled trial of telephone management of suspected urinary tract infections in women.. PubMed. 50(7). 589–94.50 indexed citations
Ebell, Mark H. & Henry C Barry. (1998). InfoRetriever: rapid access to evidence-based information on a hand-held computer.. PubMed. 15(5). 289, 292–7.17 indexed citations
18.
Barry, Henry C & Mark H. Ebell. (1997). TEST CHARACTERISTICS AND DECISION RULES. Endocrinology and Metabolism Clinics of North America. 26(1). 45–65.26 indexed citations
Barry, Henry C, et al.. (1977). Birth positions of alcoholics.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 33(1). 62–9.3 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.